Infectious diseases are caused by pathogenic microorganisms such as bacteria, viruses, fungi, and parasites.
Ask a research question about Infectious Disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Infectious Disease
creation_date: '2026-02-02T00:16:36Z'
updated_date: '2026-02-17T21:53:14Z'
category: Infectious Disease
disease_term:
preferred_term: infectious disease
term:
id: MONDO:0005550
label: infectious disease
description: >-
Infectious diseases are caused by pathogenic microorganisms such as bacteria,
viruses, fungi, and parasites.
pathophysiology:
- name: Pathogen Invasion and Replication
description: >-
Disease results from invasion and replication of pathogenic organisms in the
host, triggering host-pathogen interactions that drive tissue injury.
evidence:
- reference: PMID:36675263
reference_title: "Genomics: Infectious Disease and Host-Pathogen Interaction."
supports: SUPPORT
snippet: "Infectious diseases, which are caused by pathogens such as bacteria,
viruses, fungi, and parasites, pose a serious threat to humans, animals, and
plants"
explanation: The abstract defines infectious diseases as caused by
pathogenic microorganisms.
- name: Host Genetic Susceptibility and Immune Response
description: >-
Host genetic factors and immune response pathways influence progression from
exposure to mild or severe infection and determine disease outcomes.
biological_processes:
- preferred_term: immune response
modifier: ABNORMAL
term:
id: GO:0006955
label: immune response
evidence:
- reference: PMID:10884944
reference_title: "Host-pathogen interactions in emerging and re-emerging infectious diseases: a genomic perspective of tuberculosis, malaria, human immunodeficiency virus infection, hepatitis B, and cholera."
supports: SUPPORT
snippet: "On exposure to a pathogen, a host may resist infection, become subclinically
infected, or progress through several stages from mild to severe infection.
Chronic sequelae may or may not occur. Host factors, particularly host genes,
influence many of these stages."
explanation: The abstract describes staged progression and host genetic
influence on infectious disease outcomes.
- name: Toll-Like Receptor Signaling and Cytokine Release
description: >-
Innate immune recognition of bacterial pathogens via toll-like receptors
triggers cytokine release that supports effective immune responses.
evidence:
- reference: PMID:17280841
reference_title: "What is the role of Toll-like receptors in bacterial infections?"
supports: SUPPORT
snippet: "Innate immunity relies on signalling by Toll-like receptors (TLRs) to
alert the immune system of the presence of invading bacteria. TLR activation
leads to the release of cytokines that allow for effective innate and adaptive
immune responses."
explanation: The abstract links TLR signaling to cytokine release in
bacterial infections.
treatments:
- name: Vaccination
description: Vaccines are key preventive strategies against infectious
pathogens.
treatment_term:
preferred_term: vaccination
term:
id: MAXO:0001017
label: vaccination
evidence:
- reference: PMID:10884944
reference_title: "Host-pathogen interactions in emerging and re-emerging infectious diseases: a genomic perspective of tuberculosis, malaria, human immunodeficiency virus infection, hepatitis B, and cholera."
supports: SUPPORT
snippet: "Priorities for prevention and control of these pathogens include vaccines
and antimicrobial drugs."
explanation: The abstract lists vaccines as a priority for prevention and
control of infectious diseases.
- name: Antimicrobial Therapy
description: Antimicrobial drugs are used to treat infections caused by
pathogens.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
evidence:
- reference: PMID:10884944
reference_title: "Host-pathogen interactions in emerging and re-emerging infectious diseases: a genomic perspective of tuberculosis, malaria, human immunodeficiency virus infection, hepatitis B, and cholera."
supports: SUPPORT
snippet: "Priorities for prevention and control of these pathogens include vaccines
and antimicrobial drugs."
explanation: The abstract lists antimicrobial drugs as a priority for
infectious disease control.
references:
- reference: DOI:10.1002/mco2.662
title: 'Immunoglobulin class‐switch recombination: Mechanism, regulation, and related
diseases'
findings: []
- reference: DOI:10.1016/j.xcrm.2024.101829
title: Sepsis pathogenesis and outcome are shaped by the balance between the
transcriptional states of systemic inflammation and antimicrobial response
findings: []
- reference: DOI:10.1073/pnas.1412487111
title: Human NLRP3 inflammasome senses multiple types of bacterial RNAs
findings: []
- reference: DOI:10.1126/sciadv.abj2101
title: Neutrophil extracellular traps enhance macrophage killing of bacterial
pathogens
findings: []
- reference: DOI:10.1128/iai.00291-08
title: Impaired Opsonization with C3b and Phagocytosis of<i>Streptococcus
pneumoniae</i>in Sera from Subjects with Defects in the Classical Complement
Pathway
findings: []
- reference: DOI:10.1128/mbio.00681-25
title: Lactate metabolism is exploited by <i>Francisella tularensis</i> via
its O-antigen capsule to limit macrophage-mediated activation and cell death
findings: []
- reference: DOI:10.1128/microbiolspec.dmih2-0031-2016
title: Bloodstream Infections
findings: []
- reference: DOI:10.1146/annurev-immunol-082323-031642
title: The Integrated Pulmonary Immune Response to Pneumonia
findings: []
- reference: DOI:10.1164/ajrccm.161.supplement_1.ltta-23
title: Interactions between Leukotrienes and Other Inflammatory
Mediators/Modulators in the Microvasculature
findings: []
- reference: DOI:10.20944/preprints202405.1826.v1
title: Implications of SARS‐CoV‐2 Immunity in the Context of the Pathogenesis
of COVID‐19, Immune Evasion of the Virus, and the Effectiveness of
Vaccination
findings: []
- reference: DOI:10.3389/fimmu.2012.00389
title: Dendritic cells enhance the antigen sensitivity of T cells
findings: []
- reference: DOI:10.3389/fimmu.2013.00185
title: Multi-Faceted Functions of Secretory IgA at Mucosal Surfaces
findings: []
- reference: DOI:10.3389/fimmu.2014.00614
title: Molecular Mechanisms That Influence the Macrophage M1–M2 Polarization
Balance
findings: []
- reference: DOI:10.3389/fimmu.2018.01330
title: Trauma-Induced Damage-Associated Molecular Patterns-Mediated Remote
Organ Injury and Immunosuppression in the Acutely Ill Patient
findings: []
- reference: DOI:10.3389/fimmu.2022.963923
title: Evasion of interferon-mediated immune response by arteriviruses
findings: []
- reference: DOI:10.3389/fimmu.2024.1303115
title: 'The potential of IFN-λ, IL-32γ, IL-6, and IL-22 as safeguards against human
viruses: a systematic review and a meta-analysis'
findings: []
- reference: DOI:10.3389/fimmu.2025.1696366
title: 'Roles of cytokine storm in sepsis progression: biomarkers, and emerging
therapeutic strategies'
findings: []
- reference: DOI:10.3389/fmicb.2011.00012
title: Role of the Nlrp3 Inflammasome in Microbial Infection
findings: []
- reference: DOI:10.7759/cureus.54275
title: 'Navigating the Cytokine Storm: A Comprehensive Review of Chemokines and
Cytokines in Sepsis'
findings: []
- reference: PMID:31996461
title: Activation of Dendritic Cells Alters the Mechanism of MHC Class II
Antigen Presentation to CD4 T Cells.
findings: []
- reference: PMID:40036700
title: The Integrated Pulmonary Immune Response to Pneumonia.
findings: []
Infectious disease pathophysiology emerges from the dynamic interplay between pathogen virulence programs and host defense circuits. Innate pattern recognition by PRRs (e.g., TLRs, RLRs, NLRs, cGAS–STING/cGLRs) triggers type I/III interferon and inflammatory signaling, which in turn induces ISGs and effector programs. Excessive or mistimed responses drive tissue injury, endothelial dysfunction, and organ failure, typified by sepsis and cytokine storm; conversely, late immunosuppression and impaired antimicrobial resistance confer risk for secondary infection. Recent translational work reframes sepsis as heterogenous immune endotypes defined by opposing transcriptional states of “systemic inflammation” versus “antimicrobial resistance” and by axes of immune resistance, disease tolerance, and resilience, motivating precision immunomodulation (URLs, dates, and DOIs below) (brandesleibovitz2024sepsispathogenesisand pages 1-2, shankarhari2024reframingsepsisimmunobiology pages 6-8, shankarhari2024reframingsepsisimmunobiology pages 8-10, shankarhari2024reframingsepsisimmunobiology pages 5-6).
Mechanistic pillars: - PRR sensing and interferon programs: Viral RNA/DNA are sensed by RIG-I/MDA5 (RLRs) and cGAS–STING, while endosomal TLRs (e.g., TLR3/7/8/9) and surface TLRs (e.g., TLR2) detect viral and microbial PAMPs. Downstream IRF3/IRF7 and STAT1/STAT2–IRF9 (ISGF3) induce ISGs; dysregulation is a major determinant of disease severity in respiratory viral infections including COVID-19 (akkiz2024implicationsofsars‐cov‐2 pages 19-20). - Inflammasomes and programmed inflammatory cell death: NLRP3 activation promotes IL‑1β/IL‑18 maturation and pyroptosis; crosstalk among pyroptosis, apoptosis, and necroptosis (“PANoptosis”) amplifies cytokine storm and multi-organ dysfunction in severe infection and sepsis (you2025rolesofcytokine pages 1-2, shankarhari2024reframingsepsisimmunobiology pages 8-10). - Sepsis immunobiology: Sepsis heterogeneity reflects imbalanced resistance vs tolerance and organ-specific immune states. “Every organ has a distinctive set of immune sensors and effectors,” underscoring compartmentalized pathobiology and the need for site-specific biomarkers (shankarhari2024reframingsepsisimmunobiology pages 8-10). Transcriptional endotyping shows outcomes relate to the balance between antimicrobial “resistance” programs and a “systemic inflammation” program (brandesleibovitz2024sepsispathogenesisand pages 1-2). - Cytokine storm networks: Persistent networks including IL‑6, IL‑8, MCP‑1, IL‑10 are implicated early in acute sepsis; IL‑6 emerges as a tractable target with supportive human genetic and interventional evidence (shankarhari2024reframingsepsisimmunobiology pages 5-6, reddy2024navigatingthecytokine pages 9-10).
This framework synthesizes cross-cutting mechanisms applicable to viral, bacterial, and fungal infections. Some pathogen‑specific virulence systems (e.g., Type III/IV/VI secretion, quorum sensing, biofilms) and fungal Dectin‑1/2/complement evasion are not directly evidenced in the 2023–2024 items extracted here; they remain established contributors to pathogenesis but should be annotated with pathogen‑specific literature in subsequent iterations.
Citations: (brandesleibovitz2024sepsispathogenesisand pages 1-2, shankarhari2024reframingsepsisimmunobiology pages 6-8, shankarhari2024reframingsepsisimmunobiology pages 8-10, shankarhari2024reframingsepsisimmunobiology pages 5-6, reddy2024navigatingthecytokine pages 9-10, you2025rolesofcytokine pages 1-2, akkiz2024implicationsofsars‐cov‐2 pages 19-20)
References
(brandesleibovitz2024sepsispathogenesisand pages 1-2): Rachel Brandes-Leibovitz, Anca Riza, Gal Yankovitz, Andrei Pirvu, Stefania Dorobantu, Adina Dragos, Ioana Streata, Isis Ricaño-Ponce, Aline de Nooijer, Florentina Dumitrescu, Nikolaos Antonakos, Eleni Antoniadou, George Dimopoulos, Ioannis Koutsodimitropoulos, Theano Kontopoulou, Dimitra Markopoulou, Eleni Aimoniotou, Apostolos Komnos, George N. Dalekos, Mihai Ioana, Evangelos J. Giamarellos-Bourboulis, Irit Gat-Viks, and Mihai G. Netea. Sepsis pathogenesis and outcome are shaped by the balance between the transcriptional states of systemic inflammation and antimicrobial response. Cell Reports Medicine, 5:101829, Nov 2024. URL: https://doi.org/10.1016/j.xcrm.2024.101829, doi:10.1016/j.xcrm.2024.101829. This article has 13 citations and is from a peer-reviewed journal.
(shankarhari2024reframingsepsisimmunobiology pages 6-8): Manu Shankar-Hari, Thierry Calandra, Miguel P Soares, Michael Bauer, W Joost Wiersinga, Hallie C Prescott, Julian C Knight, Kenneth J Baillie, Lieuwe D J Bos, Lennie P G Derde, Simon Finfer, Richard S Hotchkiss, John Marshall, Peter J M Openshaw, Christopher W Seymour, Fabienne Venet, Jean-Louis Vincent, Christophe Le Tourneau, Anke H Maitland-van der Zee, Iain B McInnes, and Tom van der Poll. Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies. The Lancet Respiratory Medicine, 12:323-336, Apr 2024. URL: https://doi.org/10.1016/s2213-2600(23)00468-x, doi:10.1016/s2213-2600(23)00468-x. This article has 102 citations and is from a highest quality peer-reviewed journal.
(shankarhari2024reframingsepsisimmunobiology pages 8-10): Manu Shankar-Hari, Thierry Calandra, Miguel P Soares, Michael Bauer, W Joost Wiersinga, Hallie C Prescott, Julian C Knight, Kenneth J Baillie, Lieuwe D J Bos, Lennie P G Derde, Simon Finfer, Richard S Hotchkiss, John Marshall, Peter J M Openshaw, Christopher W Seymour, Fabienne Venet, Jean-Louis Vincent, Christophe Le Tourneau, Anke H Maitland-van der Zee, Iain B McInnes, and Tom van der Poll. Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies. The Lancet Respiratory Medicine, 12:323-336, Apr 2024. URL: https://doi.org/10.1016/s2213-2600(23)00468-x, doi:10.1016/s2213-2600(23)00468-x. This article has 102 citations and is from a highest quality peer-reviewed journal.
(shankarhari2024reframingsepsisimmunobiology pages 5-6): Manu Shankar-Hari, Thierry Calandra, Miguel P Soares, Michael Bauer, W Joost Wiersinga, Hallie C Prescott, Julian C Knight, Kenneth J Baillie, Lieuwe D J Bos, Lennie P G Derde, Simon Finfer, Richard S Hotchkiss, John Marshall, Peter J M Openshaw, Christopher W Seymour, Fabienne Venet, Jean-Louis Vincent, Christophe Le Tourneau, Anke H Maitland-van der Zee, Iain B McInnes, and Tom van der Poll. Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies. The Lancet Respiratory Medicine, 12:323-336, Apr 2024. URL: https://doi.org/10.1016/s2213-2600(23)00468-x, doi:10.1016/s2213-2600(23)00468-x. This article has 102 citations and is from a highest quality peer-reviewed journal.
(akkiz2024implicationsofsars‐cov‐2 pages 19-20): Hikmet Akkiz. Implications of sars‐cov‐2 immunity in the context of the pathogenesis of covid‐19, immune evasion of the virus, and the effectiveness of vaccination. May 2024. URL: https://doi.org/10.20944/preprints202405.1826.v1, doi:10.20944/preprints202405.1826.v1.
(you2025rolesofcytokine pages 1-2): Weibin You. Roles of cytokine storm in sepsis progression: biomarkers, and emerging therapeutic strategies. Frontiers in Immunology, Nov 2025. URL: https://doi.org/10.3389/fimmu.2025.1696366, doi:10.3389/fimmu.2025.1696366. This article has 4 citations and is from a peer-reviewed journal.
(reddy2024navigatingthecytokine pages 9-10): Harshitha Reddy, Chaitanya Kumar Javvaji, Suprit Malali, Sunil Kumar, Sourya Acharya, and Saket Toshniwal. Navigating the cytokine storm: a comprehensive review of chemokines and cytokines in sepsis. Cureus, Feb 2024. URL: https://doi.org/10.7759/cureus.54275, doi:10.7759/cureus.54275. This article has 26 citations and is from a poor quality or predatory journal.
Infectious disease pathophysiology represents one of the most complex interfaces in modern biology, encompassing the intricate molecular and cellular mechanisms by which pathogens establish infection, evade host defenses, and ultimately produce clinical disease manifestations. This report synthesizes contemporary understanding of how bacterial and viral pathogens manipulate host cellular machinery, engage with immune surveillance systems, and progress through distinct pathological stages. The fundamental basis of infectious disease involves a dynamic interplay between pathogenic virulence factors—including adhesins, toxins, and immune evasion mechanisms—and host defense strategies spanning innate recognition through adaptive immunity. Understanding these mechanisms at the molecular level provides essential insights into disease progression, tissue damage, and the ultimate clinical outcomes that define infectious diseases.
The initiation of infectious disease begins with pathogen attachment to host cells, a process fundamentally dependent on specific receptor-ligand interactions that determine both tropism and host range susceptibility[3]. Viral and bacterial pathogens have evolved highly specialized molecular strategies to exploit host cell surface molecules as entry portals. For example, human immunodeficiency virus (HIV) requires sequential interactions with the CD4 molecule expressed on helper T cells, followed by conformational changes that permit engagement with either the CCR5 or CXCR4 coreceptor molecules[3]. This CD4-CCR5/CXCR4 interaction cascade directly determines viral tropism for CD4-positive helper T cells, the major targets for HIV replication, and consequently drives the progressive loss of these critical immune regulatory cells that ultimately leads to immune suppression and susceptibility to opportunistic infections[3]. The importance of these viral-receptor interactions extends beyond simple attachment; they dictate which cellular populations become infected, where viral replication occurs within the body, and ultimately which tissues experience pathological damage.
Bacterial pathogens similarly utilize host cell surface receptors to mediate invasion, though their mechanisms frequently involve more complex interactions with extracellular matrix components and integrin molecules. The gram-positive pathogen Staphylococcus aureus demonstrates sophisticated receptor engagement through its fibronectin-binding proteins (FnBPs), which interact with host fibronectin within the extracellular matrix and subsequently engage the α5β1 integrin expressed on mammalian cell surfaces[21]. This fibronectin-bridged interaction facilitates bacterial internalization through a process involving integrin clustering and recruitment of focal adhesion complex proteins including vinculin, paxillin, and focal adhesion kinase[21]. The binding specificity and affinity of bacterial adhesins for host receptors can vary among different strains, with clinical observations demonstrating that S. aureus bacteremia isolates infecting cardiac devices exhibit higher fibronectin-binding affinity than strains causing only uncomplicated bacteremia, suggesting that adhesin-mediated tropism directly influences infection severity and site-specific dissemination[21].
The Yersinia species employ an alternative invasion strategy through their invasin protein, which binds with high affinity to β1-integrin receptors on the surface of M cells overlying Peyer's patches in the gastrointestinal tract[21]. Following initial attachment and invasion mediated by invasin, bacterial adhesion is maintained through expression of alternative adhesins YadA and Ail, which promote tight adherence to extracellular matrix proteins fibronectin and collagen[21]. This multi-step adhesion strategy demonstrates how pathogenic bacteria orchestrate sequential molecular interactions to establish stable contacts with host tissues and prevent clearance during the critical early stages of infection.
Beyond simple receptor recognition, bacterial pathogens actively manipulate host cytoskeletal architecture to facilitate their internalization into host cells. Membrane ruffling represents a major virulence mechanism employed by numerous pathogens including Yersinia, Listeria monocytogenes, Salmonella, and Shigella flexneri[1]. This process occurs through bacteria-induced actin polymerization within host cells, driven by bacterial effector proteins that are translocated into the host cytoplasm via specialized secretion systems. Salmonella and Shigella bacteria adhere to host cell surfaces and directly secrete proteins that are translocated into the host cell cytoplasm, where they trigger actin polymerization and branching of actin filaments[1]. This three-stage process is controlled by distinct bacterial proteins, with the first stage initiating actin nucleation and filament branching, the second stimulating actin polymerization and depolymerization, and the third terminating the process[1]. The result is dramatic cellular reorganization that creates membrane protrusions and facilitates bacterial uptake through processes morphologically distinct from conventional endocytosis.
The cytoskeletal changes induced by pathogenic bacteria extend beyond membrane ruffling to produce fundamental alterations in host cell permeability and ion homeostasis. Proteins and protein kinases involved in actin breakdown are activated during bacterial invasion, resulting in disruption of microvilli and alterations in the cytoskeleton that increase cellular permeability to ions and water[1]. In the case of secretory diarrhea-causing pathogens, ions are actively secreted resulting from these cytoskeletal perturbations, producing the characteristic watery diarrhea and electrolyte losses that define toxin-mediated enteric disease[1]. These cellular changes demonstrate how pathogenic manipulation of host cytoskeletal proteins produces not merely bacterial internalization but also the tissue-level pathological consequences that manifest as clinical disease.
Bacterial pathogens produce diverse toxin molecules that directly damage host cells and tissues through highly specific mechanisms of action. The distinction between endotoxins and exotoxins represents a fundamental classification reflecting both structural differences and mechanistic properties[19][20]. Lipopolysaccharide (LPS), the prototypical endotoxin, is a major component of the gram-negative bacterial cell envelope composed of lipid A, a core oligosaccharide region, and variable O-antigen polysaccharide chains[19][20]. During infection and disease progression, gram-negative bacteria release endotoxin either when cells die and the membrane disintegrates or during active binary fission[19]. The lipid A component of endotoxin is responsible for the potent toxic properties of the LPS molecule, acting as a pathogen-associated molecular pattern recognized by innate immune receptors[20]. When released into circulation, lipid A from lysed bacterial cells causes fever, diarrhea, and in severe cases can precipitate fatal endotoxic septic shock—a manifestation of overwhelming immune activation[23].
The recognition of lipid A by host cells occurs through the CD14/TLR4/MD2 receptor complex predominantly expressed on monocytes, dendritic cells, macrophages, and B cells[23]. This recognition triggers robust downstream signaling cascades that include recruitment of adaptor proteins such as myeloid differentiation factor 88 (MyD88), activation of IRAK family kinases, and subsequent phosphorylation of nuclear factor-κB (NF-κB) and mitogen-activated protein kinases (MAPK)[2]. These transcription factors collectively facilitate upregulation of pro-inflammatory cytokines and type I interferons, initiating the systemic inflammatory response characteristic of endotoxemia[2].
In contrast to endotoxins, bacterial exotoxins are protein molecules produced by living pathogens with highly specific and potent mechanisms of cellular damage[19]. Exotoxins differ fundamentally from endotoxins in their specificity, heat stability, and lethal potency. While endotoxin stimulates general systemic inflammatory responses and maintains stability at high temperatures, exotoxins target specific cell types through receptor-mediated mechanisms and are heat-labile, being denatured at temperatures above 41°C[19]. The extraordinary potency of exotoxins is demonstrated by botulinum toxin, which causes botulism and possesses a lethal dose (LD₅₀) of 0.000001 mg/kg—approximately 240,000 times more lethal than endotoxin[19].
The mechanistic diversity of exotoxins reflects their classification into three major categories based on targeted cellular components and mechanisms of action: intracellular targeting toxins, membrane-disrupting toxins, and superantigens[19]. Intracellular targeting toxins comprise A-B exotoxins, where the B component mediates cellular specificity through binding to specific cell surface receptors while the A component delivers the catalytic activity into the cytoplasm[19]. Botulinum toxin, for example, operates through a three-stage process wherein the toxin first binds to specific receptors on nerve cell endings, is then internalized by endocytosis into acidified vesicles that induce conformational changes permitting translocation to the cytosol, and finally cleaves cell neuroproteins called synaptopeptidases that prevent acetylcholine release[1]. This mechanism produces the characteristic paralysis of botulism through selective blockade of neuromuscular acetylcholine signaling.
Pore-forming toxins represent another major category of exotoxins that directly compromise cellular membrane integrity. Alpha-toxin produced by Staphylococcus aureus forms pores in host cell membranes, inserting viral proteins into the membrane structure and disrupting normal ion and water homeostasis[1]. The downstream consequences extend beyond simple lysis, as alpha-toxin also activates the arachidonic acid cascade resulting in thromboxane- and prostacyclin-mediated vasoconstriction despite concurrent edema formation, and acts directly on platelets to release procoagulant factors that drive pathological coagulation[1]. These effects demonstrate how a single toxin molecule produces multiple layers of tissue damage extending from direct cellular destruction to systemic vascular and hemostatic perturbations.
Superantigen toxins represent yet another virulence mechanism wherein toxin molecules bypass normal antigen processing and directly cross-link major histocompatibility complex molecules on antigen-presenting cells with T cell receptors on T lymphocytes[1]. The superantigen toxin of S. aureus forms a bridge between major histocompatibility complex receptors on macrophages and T cell receptors, resulting in massive release of interleukin-2 (IL-2)[1]. The downstream consequence is profound T cell proliferation and induction of type 1 cytokines that stimulate release of proinflammatory cytokines from macrophages, generating the systemic inflammatory manifestations and potential toxic shock syndrome that define superantigen-mediated pathology[1].
Many pathogenic bacteria employ sophisticated strategies to survive within the intracellular environment of professional phagocytic cells that normally function to destroy internalized microorganisms. The normal phagolysosomal fusion process involves initial fusion of phagocytic vesicles with host cell endosomes, followed shortly thereafter by fusion with lysosomes containing degradative enzymes and reactive oxygen species[1]. Extended survival and replication in the phagosome represents an important strategy for dissemination of bacteria, achieved through two main mechanisms: inhibition of phagolysosomal fusion and blockage of lysosomal enzyme formation following phagocytosis[1].
Listeria employs a strategy of phagosomal maturation modulation by delaying fusion with the lysosome before escape from the phagosome[1]. In contrast, Salmonella appears to actually induce formation of a phagolysosome but demonstrates remarkable survival within this acidified, enzyme-rich compartment[1]. This survival is achieved through rapid upregulation of reactive oxygen species (ROS) resistance genes within 20 minutes of intracellular uptake, allowing bacterial populations to resist the oxidative stress generated within phagolysosomes[1]. The molecular basis of this ROS resistance involves expression of catalase and superoxide dismutase enzymes that neutralize reactive oxygen species that would otherwise destroy the bacterial cell[1].
Rickettsia, Neorickettsia, and Rhodococcus species employ an alternative strategy of directly inhibiting phagolysosomal fusion itself, preventing the acidification and enzymatic activation that would otherwise kill internalized bacteria[1]. This diversity of phagolysosomal survival mechanisms demonstrates how different bacterial species have evolved distinct molecular strategies to persist within host cells, each representing potential therapeutic targets for future antimicrobial interventions.
Pathogenic bacteria have evolved sophisticated mechanisms to disrupt the complement system, a critical component of innate immunity responsible for bacterial opsonization, direct killing through membrane attack complex formation, and inflammation through generation of anaphylatoxins[26]. Staphylococcus aureus surface proteins directly target complement system components as a primary immune evasion strategy. Staphylococcal immunoglobulin binding protein (Sbi) depletes complement factor 3 (C3) from the bacterial surface[2], preventing the deposition of C3b fragments that would otherwise facilitate phagocytic recognition and bacterial destruction[26]. Additionally, the chemotaxis inhibitory protein of S. aureus (CHIPS) hinders the function of complement factor C5a[2], effectively suppressing recruitment of neutrophils to sites of infection by blocking C5a-mediated chemotaxis and blocking formylated peptide receptors on neutrophils required for neutrophil chemotaxis[2].
Salmonella and other gram-negative pathogens employ an alternative complement evasion strategy through adaptive structural modification of their lipopolysaccharide (LPS). During chronic Pseudomonas aeruginosa infection, the bacterial LPS undergoes adaptive structural and synthetic changes resulting in lipid A modification through acetylation, loss of O antigen polysaccharide, and downregulation of LPS synthesis[2]. These adaptive changes represent sophisticated mechanisms that Pseudomonas exploits to escape immune system recognition, potentially through becoming unrecognizable to TLR4 and complement-dependent recognition systems[2]. The ability of bacteria to modify their surface antigens in response to specific immune pressure demonstrates the dynamic nature of host-pathogen interactions wherein prolonged infection selects for bacterial variants with enhanced immune evasion capacity.
Viral pathogenesis describes the processes by which viral infections cause disease and involves virus-host interactions at both cellular and systemic levels[3]. The determination of viral tissue tropism—the specific tissues and cell types that a virus can infect—depends critically on interactions between viral proteins and host cell surface receptors[3]. Several rhinoviruses bind to ICAM-1 (CD54), a process that promotes viral infection of the cell[3]. In contrast, herpes simplex virus employs a multi-step attachment strategy, utilizing heparin sulfate to facilitate initial viral attachment to the cell, followed by engagement of specific host receptor proteins on the cell surface that mediate actual viral entry into the cell[3]. These differential attachment strategies highlight how pathogenic viruses have evolved specialized molecular recognition systems optimized for their particular replication requirements.
Hepatitis C virus (HCV) tropism for hepatocytes within the liver is determined by the host microRNA miR-122, a 20-22 nucleotide host RNA that regulates multiple biological processes within infected cells[3]. The importance of this viral-host microRNA interaction for HCV replication and disease pathogenesis is illustrated by studies in a chimpanzee model where administration of a miR-122-specific antagonist resulted in decreased viral loads within the liver and reduction in HCV-associated disease signs[3]. This example demonstrates that viral interactions with proviral host factors, including endogenous microRNAs and other regulatory molecules, directly influence viral replication capacity and drive pathogenic disease development[3].
Viruses have evolved multiple sophisticated strategies to block components of the type I interferon signaling cascade, a critical host antiviral defense mechanism[3]. The interferon response begins with recognition of viral pathogen-associated molecular patterns through pattern recognition receptors including retinoic acid-inducible gene-I (RIG-I), melanoma differentiation-associated protein 5 (MDA5), cyclic GMP-AMP synthase (cGAS), and interferon-inducible protein 16 (IFI16)[27][30]. Upon activation of these sensors, downstream signaling recruits MAVS (mitochondrial antiviral signaling protein) as a protein-complex assembly scaffold that coordinates activation of tank-binding kinase 1 (TBK1) and inhibitor of nuclear factor kappa-B kinase subunit ε (IKKε)[27]. These activated kinases subsequently phosphorylate interferon regulatory factors 3 and 7 (IRF3/IRF7), which translocate to the nucleus and induce expression of type I interferons that establish an antiviral state in infected and neighboring cells[27].
Viral immune evasion strategies targeting this pathway operate through five major tactical categories: inhibition of critical sensor or adaptor proteins; shielding or processing viral immunostimulatory RNA; degrading or cleaving sensors or downstream signaling mediators; relocalizing or 'seizing' innate signaling proteins; and derailing interferon receptor signaling[27]. Herpes simplex virus 1 (HSV-1) UL37 protein collaborates with host glutamine amidotransferase PPAT to induce RIG-I deamidation, thereby deactivating RNA sensing at the earliest stages of viral recognition[27]. Additionally, HSV-1 UL37 targets cGAS for deamidation, impairing its enzymatic capacity for cGAMP synthesis[27]. The HSV-1-encoded kinase US3 phosphorylates RIG-I specifically at serine 8, preventing effective RIG-I signaling[27]. These diverse viral strategies targeting single host sensor proteins demonstrate the evolutionary pressure viruses face from host interferon responses and the selective advantage of acquiring interferon-antagonistic mechanisms.
Once type I interferons are produced and secreted following viral infection, they bind to interferon-alpha/beta receptors (IFNAR) on the surface of infected and neighboring cells, activating the intracellular Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway[27]. During this critical process, STAT1 and STAT2 become phosphorylated and combine with interferon regulatory factor 9 (IRF9) to form the interferon-stimulated gene factor 3 (ISGF3) transcriptional complex[27]. This complex localizes to the nucleus and binds promoters containing interferon-stimulated response elements (ISREs) to drive expression of interferon-stimulated genes (ISGs), which mediate direct antiviral effector functions and modulate the host immune response[3]. Viruses have evolved mechanisms to antagonize this protective response at multiple steps. For example, influenza virus hemagglutinin (HA) promotes IFNAR1 degradation, effectively preventing the cell from responding to interferon signals[27]. Some viruses such as vaccinia virus employ a 'decoy' tactic to sequester interferons prior to IFNAR binding, preventing autocrine and paracrine interferon signaling[27].
Arteriviruses, including porcine reproductive and respiratory syndrome virus (PRRSV), employ diverse mechanisms to suppress interferon responses through interference with multiple stages of the interferon signaling cascade[30]. PRRSV infection leads to weak induction of natural immune responses, with interferon maintained at very low levels, suggesting direct interference with interferon-β gene transcription in early infection stages[30]. At least two structural proteins (M and N proteins) and four nonstructural proteins of PRRSV exhibit inhibitory effects on interferon-β promoter activation, with nonstructural protein 1 (nsp1) showing the strongest inhibitory effect[30]. PRRSV nsp4 inhibits virus-induced interferon-β production by targeting NEMO (NF-κB essential modulator) for protein cleavage at four specific sites[30]. The 3C-like proteinase of PRRSV cleaves MAVS in a proteasome- and caspase-independent manner, preventing MAVS-dependent activation of downstream interferon signaling kinases[30]. These multiple parallel mechanisms of interferon antagonism demonstrate the critical importance of this antiviral pathway and the substantial evolutionary investment viruses have made in developing countermeasures.
Innate immunity relies fundamentally on signaling by Toll-like receptors (TLRs) to alert the immune system to the presence of invading bacteria and viral pathogens[7]. Functional characterization of TLRs has established that innate immunity represents a skillful system detecting invasion of microbial pathogens through recognition of conserved pathogen-associated molecular patterns[10]. Recognition of microbial components by TLRs initiates signal transduction pathways that trigger expression of genes controlling innate immune responses and instructing development of antigen-specific acquired immunity[10]. TLR signaling pathways are finely regulated by TIR domain-containing adaptors, including MyD88, TIRAP/Mal, TRIF and TRAM, with differential utilization of these adaptor proteins providing specificity to individual TLR-mediated signaling pathways[10].
A critical role of TLR4 was initially characterized in the recognition of the microbial component lipopolysaccharide (LPS), with subsequent research rapidly establishing that individual TLRs recognize specific microbial components derived from bacterial, fungal, protozoal and viral pathogens[10]. TLR5 recognizes flagellin, a monomeric constituent of bacterial flagella, through close physical interaction between the TLR5 receptor and the flagellin molecule[10]. TLR7 and human TLR8 recognize guanosine- or uridine-rich single-stranded RNA from viruses such as HIV, vesicular stomatitis virus, and influenza virus[10]. Importantly, while single-stranded RNA is abundant within host cells, host-derived RNA is typically not detected by TLR7 or TLR8, likely because these receptors are expressed in endosomes where host-derived RNA is not normally delivered[10]. In contrast, viral infection results in endosomal delivery of viral RNA, permitting TLR7/TLR8-dependent recognition and triggering of interferon responses[10].
Upon TLR activation, the canonical signaling cascade involves recruitment of adaptor proteins such as MyD88 to the TIR domain of the activated TLR[2]. MyD88 subsequently activates downstream signaling targets including IRAK family kinases, resulting in activation of transcription factors including NF-κB, mitogen-activated protein kinases (MAPK), and activator protein-1 (AP-1)[2]. These transcription factors collectively facilitate upregulation of pro-inflammatory cytokines and type I interferon transcription[2]. Several mechanisms have been elucidated that negatively control TLR signaling pathways, thereby preventing overactivation of innate immunity that would lead to fatal immune disorders[10]. The involvement of TLR-mediated pathways in autoimmune and inflammatory diseases has been proposed, indicating that proper regulation of these critical recognition systems is essential for maintaining immune homeostasis[10].
The NLRP3 inflammasome represents a crucial intracellular recognition platform that senses both pathogenic microorganisms and danger signals released during cellular damage[47]. The NLRP3 inflammasome is generally believed to require a two-signal mechanism for complete activation[47]. The first signal, typically initiated by TLR activation through lipopolysaccharide (LPS), leads to nuclear factor-κB (NF-κB) dependent synthesis of precursor forms of the pro-inflammatory cytokines interleukin-1β (IL-1β) and interleukin-18 (IL-18), as well as upregulation of NLRP3 itself[47]. The second signal, provided by diverse stimuli including adenosine triphosphate (ATP) through the P2X7 receptor, results in potassium (K⁺) efflux through membrane pores that triggers NLRP3 inflammasome assembly[47]. Alternative mechanisms bypass the requirement for the second signal; for example, Streptococcus pyogenes produces the pore-forming toxin streptolysin O (SLO) which independently activates the NLRP3 inflammasome in a P2X7R-independent manner[47].
Upon NLRP3 inflammasome assembly consisting of the adaptor molecule ASC and pro-caspase-1, caspase-1 becomes activated and cleaves pro-IL-1β and pro-IL-18 into their active forms for secretion[47]. Caspase-1 also cleaves gasdermin D (GSDMD), and the N-terminal fragment of GSDMD oligomerizes to form pores in the plasma membrane, initiating a form of immunogenic cell death termed pyroptosis[28]. Pyroptosis differs fundamentally from apoptosis in that it represents a proinflammatory programmed cell death pathway wherein pyroptotic cells rupture their membranes and release intracellular contents including damage-associated molecular patterns (DAMPs) and processed inflammatory cytokines[25]. The physiological insults resulting from pathogen-associated molecular pattern (PAMP) exposure that can drive NLRP3 activation include K⁺ efflux, lysosomal damage, and reactive oxygen species (ROS) production[47]. Human NLRP3 inflammasome activation has been demonstrated to respond to all three types of bacterially-derived RNA—messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNAs)—as well as synthetic 20-guanosine single-stranded RNA[44]. These diverse PAMP specificities indicate that the NLRP3 inflammasome serves as a broad-spectrum intracellular recognition system for bacterial infection and cellular danger.
Humoral immunity, mediated by B lymphocytes and their plasma cell derivatives, represents the second major pillar of adaptive immunity providing targeted defense against pathogens[9][12]. B lymphocytes originate in the bone marrow and circulate via the bloodstream, where they play key roles in the adaptive immune response to pathogenic challenges[9]. Upon appropriate stimulation by helper T lymphocytes, B lymphocytes differentiate into plasma cells that produce antibodies against specific pathogenic antigens[9]. The humoral immune system specifically addresses antigens of freely circulating pathogens or antigens located outside infected cells, producing antibodies that bind pathogenic antigens and prevent them from completely entering host cells[9]. Each B cell produces antibodies specifically created to fight against a particular pathogen, allowing these cells to bind many different target antigens and prevent multiple different types of infections through immune exclusion[9].
Antibodies produced by plasma B cells function through several direct and indirect immune mechanisms. The neutralization of infectious agents occurs through antibody binding to and blocking of critical pathogenic molecules or through antibody-dependent cellular cytotoxicity[9]. Antibodies activate the complement system, a critical innate immune component that increases the ability of antibodies and lymphocytes to remove pathogens and infected cells from the body[9]. Antibodies bind foreign substances to facilitate their destruction through opsonization and phagocytosis, wherein antibody-coated pathogenic particles are more efficiently recognized and destroyed by professional phagocytes[9]. Antibodies neutralize antigens primarily through mechanisms of attachment and accumulation; the aggregation of neutralizing antibodies on matching viral particles with the antigen inhibits the ability of virus to infect other cells[9]. Furthermore, antibodies can participate in processes leading to lysis or killing of infectious cells through activation of the complement cascade or interaction with effector cells and release of cytokines[9].
During the germinal center response, B cells undergo class switch recombination (CSR), a process converting initial IgM antibodies to other immunoglobulin isotypes including IgG, IgA, and IgE[56]. Class switch recombination involves DNA recombination that replaces the immunoglobulin constant region with one encoding the appropriate isotype for optimal pathogen protection[56]. Recent findings have established that class switch recombination occurs during initial T cell-B cell interactions prior to germinal center formation, rapidly declining as B cells differentiate into germinal center cells and somatic hypermutation commences[56]. This early CSR ensures that different antibody isotypes are generated rapidly during the primary immune response, with approximately 70% of germinal center B cells having completed class switching by days 4.5 to 6.5 post-immunization[56].
Cell-mediated immunity, orchestrated by T lymphocytes, represents the adaptive immune response type that does not produce antibodies but instead activates CD8+ cytotoxic T cells, natural killer cells, and macrophages[9]. This cellular immunity plays particular importance in controlling viral, chlamydial, rickettsial, and protozoal infections wherein antibodies cannot penetrate and attack intracellular pathogens that multiply within host cells[9]. T cell activation begins when naive T cells encounter cognate antigen presented by major histocompatibility complex (MHC) molecules on dendritic cells in secondary lymphoid organs[32]. Recognition of MHC-antigen complexes induces basal activation of the T cell receptor (TCR) complex and increased T cell responsiveness toward subsequent encounters with cognate antigens through a process termed tonic TCR signaling[32].
CD4+ helper T cells coordinate further targeted inflammatory responses from both innate and adaptive immune cells, while CD8+ killer T lymphocytes orchestrate targeted destruction of infected cells[38]. When CD8+ T cells develop effector functions, they convert into cytotoxic T cells capable of attacking cells directly and destroying those that are malignant or infected with virus[12]. Cytotoxic T cells exert this function by inducing apoptosis in target cells through liberation of cytolytic granules or through expression of ligands for death receptors such as Fas ligand (CD95)[12]. The importance of CD4+ T cell help to CD8+ T cell responses cannot be overstated; CD4+ T cells are essential for formation of protective memory CD8+ T cells following infection or immunization[60]. CD4+ T cell help influences the epigenetic state of memory CD8+ T cells, with helpless CD8+ T cells displaying reduced acetylation at the interferon-gamma (IFNγ) locus and increased methylation at the interleukin-2 (IL-2) promoter resulting in reduced responsiveness upon antigen re-stimulation[60].
Regulatory T cells (Treg) represent a specialized CD4+ T cell subset whose function is to inhibit immune responses, modulating the immune system to tolerate self-antigens and prevent autoimmune diseases[12]. Regulatory T cells modulate the maturation state of dendritic cells through leukocyte-associated antigen 1 (LFA-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA4)-mediated regulation of CD80/CD86 expression, influencing dendritic cell ability to stimulate CD8+ T cells during priming[60]. T regulatory cells regulate the stability of interactions between dendritic cells and CD8+ T cells through suppression of chemokine production by dendritic cells, and are critical for development of high-avidity effector and memory CD8+ T cells[60].
Memory T cells represent a critical component of protective immunity against intracellular pathogens, characterized by their capacity to survive long-term and undergo rapid and robust proliferation and acquisition of effector function upon antigen re-exposure[57]. CD4+ resident memory T cells dominate immunosurveillance in non-lymphoid tissues following viral infection, with these cells expressing phenotypic, transcriptional, and functional properties similar to CD8+ resident memory T cells inhabiting similar tissue locations[57]. Tissue-resident CD4+ T cells maintain expression of adhesion markers including CD69 that promote stable tissue residence and reduce recirculation through lymphoid tissues[57]. Reactivation of mucosal CD4+ resident memory T cells triggers rapid local immune activation including expression of granzyme B and CD11c high MHC-II high classical dendritic cell maturation[57].
The release of several pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6) from activated immune cells causes the lung's alveolar cells to attract macrophages, T cells, and B cells, which triggers an inflammatory response characteristic of respiratory infection[8]. The severity of viral infection and mortality rate are both positively correlated with unchecked and dysregulated release of inflammatory and pro-inflammatory cytokines[8]. In SARS-CoV-2 infection, IL-6 levels increase significantly in mild COVID-19 patients and become markedly elevated in severe COVID-19 patients, with serum IL-6 levels showing a significant relationship with disease progression severity[8]. Patients in the severe group had significantly higher serum ferritin, C-reactive protein (CRP), and erythrocyte sedimentation rate levels than those in mild and healthy control groups[8].
Pro-inflammatory cytokines including interleukin-1β (IL-1β), interleukin-6 (IL-6), interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), interleukin-15 (IL-15), and interleukin-17 (IL-17) were present in higher concentrations in Middle East respiratory syndrome coronavirus (MERS-CoV) patients, correlating with disease severity[8]. These cytokines enhance viral neutralization, reduce viral replication, and promote apoptosis of viral-infected cells[11]. Pro-inflammatory cytokines regulate immune system communication and serve as mediators in defense against viral pathogens, enhancing antigen presentation by major histocompatibility complex molecules and stimulating cell-mediated immune cells such as natural killer cells, cytotoxic T cells, and CD8+ T cells[11]. The collective findings emphasize that exogenously administered pro-inflammatory cytokines, specifically interferon-lambda (IFN-λ) and interleukin-32 (IL-32), exhibit significant antiviral activity, underscoring them as potent antiviral agents[11].
Interferon-gamma (IFNγ) represents one of the primary immunometabolic regulators that is crucial in shaping host metabolism during infections[39]. As a pleiotropic cytokine produced by activated T cells and natural killer cells, IFNγ regulates various immune functions including macrophage activation, antigen presentation, and direct antiviral defense[39]. Beyond its immunological effects, IFNγ exerts several metabolic influences, modulating glucose metabolism at both systemic and cellular levels to ensure optimal immune responses while restricting viral replication[39]. During infection, IFNγ stimulates hepatic gluconeogenesis, redistributing glucose from peripheral tissues toward immune cells[39]. This systemic glucose redistribution supplies immune cells, particularly T cells and macrophages, with adequate energy supplies during active immune response[39]. However, the long-lasting elevation of gluconeogenesis can contribute to hyperglycemia and insulin resistance observed during chronic infections and inflammatory diseases[39].
Neutrophils are critical for host defense against infection and represent the first immune cells to arrive at infection sites armed to clear invading pathogens[48]. Central to neutrophil function is infiltration into damaged tissues mediated by a multistep process requiring coordination between both immune and nonimmune cells[53]. The chemokine CXCL8 (also known as interleukin-8 or IL-8) represents one of the most well-studied chemokines and a key factor facilitating neutrophil recruitment[53]. CXCL8 was originally identified as a "novel cytokine that activates neutrophils," following discoveries of other neutrophil chemotactic factors including the bacterial peptide formyl-methionyl-leucyl-phenylalanine (fMLP), anaphylatoxin C5a, and leukotriene B4 (LTB₄)[53]. Upon CXCL8 treatment, neutrophils show increases in cytosolic calcium (Ca²⁺), undergo shape changes, generate superoxide, and undergo granule exocytosis[53].
Neutrophils combat extracellular pathogens by secreting neutrophil extracellular traps (NETs) consisting of DNA studded with antimicrobial peptides through a process termed NETosis[31]. Within 5 to 60 minutes of engaging Staphylococcus aureus, vital NETosis results in exocytosis of NETs leaving the cell membrane intact, while suicidal NETosis occurring after 2 to 4 hours causes rupture of the cell membrane through terminal NET release[31]. Increased suicidal NETosis does not provide advantage in neutrophil-mediated killing of bacterial pathogens in isolation but rather augments macrophage killing in response to multiple phylogenetically distinct pathogens, including S. aureus, Streptococcus pneumoniae, and Pseudomonas aeruginosa[31]. Net formation increases antibacterial activity of macrophages by facilitating phagocytosis of bacteria and transferring biologically active neutrophil-specific antimicrobial peptides to macrophages[31]. These results demonstrate that NET formation acts as a conduit for neutrophils to enhance antibacterial activity of macrophages, with accelerated and more robust suicidal NETosis making neutrophils more adept at increasing antibacterial activity of macrophages against multiple bacterial pathogens[31].
During migration toward sites of infection, neutrophil transmigration from peripheral blood through the endothelial layer to reach inflamed tissue depends critically on integrins, adhesion molecules present on all immune cells[48]. Neutrophils express primarily β2-integrins, including β2αM (complement receptor 3 or macrophage-1 antigen), β2αL (lymphocyte function-associated antigen 1), and β2αX (CR4 or gp150/95)[48]. During the multistep cascade of neutrophil recruitment, neutrophils first roll along vessel walls via P-selectin glycoprotein ligand-1 (PSGL-1) binding to P-selectin or E-selectin on vascular endothelium, which slows their speed significantly[48]. Subsequently, extracellular stimuli mostly activating G-protein coupled receptors (GPCR) on neutrophils initiate β2-integrin inside-out signaling, shifting integrins into an active state[48]. These active β2-integrins subsequently bind their ligands; for CR3 (β2αM), the ligand is intercellular adhesion molecule 1 (ICAM-1), enabling neutrophils to stop rolling and adhere to the vessel wall[48]. Finally, neutrophils crawl over vessel endothelium in search of a suitable location to transmigrate, either paracellularly or rarely transcellularly, into underlying tissues[48].
Following tissue trauma or during severe infection, numerous mediators known as damage-associated molecular patterns (DAMPs) are released into the bloodstream by injured tissues[51]. High-mobility group box 1 protein (HMGB1) represents one of the most described DAMPs, released during severe trauma and identified as a key player in overwhelming sterile inflammatory responses[51][54]. HMGB1 contains two redox-sensitive cysteine sites that deeply impact its function; during severe trauma with excessive production of reactive oxygen species, enhanced oxidative stress leads to multiple redox reactions that shift HMGB1 function from chemotactic signaling (reduced form) toward severe pro-inflammatory activity (oxidized form)[51]. At opposite extremes, the reduced form of HMGB1 rather enhances chemotactic signaling[51]. Interestingly, HMGB1 has poor pro-inflammatory activity in isolation but acts as a cofactor of inflammation when complexed with lipopolysaccharide, nuclear DNA, or interleukin-1β[51].
The fully reduced HMGB1 serves as a damage signal that recruits monocytes and leukocytes, forming a complex with CXCL12 to initiate leukocyte recruitment through CXCR4 interaction[54]. This reduced form activates the NF-κB pathway through TLR2/4/9 to induce pro-inflammatory cytokine secretion including IL-6 and TNF-α from monocytes[54]. In contrast, the fully oxidized sulfonate form of HMGB1 predominantly mediates immunosuppression during apoptosis via engagement of the receptor for advanced glycation end-products (RAGE)[54]. Pretreatment with HMGB1 diminishes production of TNF-α induced by LPS in macrophages and attenuates phagocytic activity through inhibition of NF-κB and MAPK/JNK pathways[54]. Neutrophils pretreated with HMGB1 exhibit notably diminished generation of reactive oxygen species, while clinical correlation analysis indicates significant negative correlation between plasma HMGB1 levels and neutrophil ROS production in patients with septic shock[54].
The incubation period occurs immediately after initial entry of the pathogen into the host and represents the time during which the pathogen multiplies within host tissues[37][40]. During this initial stage, pathogenic particles multiply but remain at insufficient numbers to cause detectable signs or symptoms of disease[37][40]. Incubation periods vary dramatically depending on the specific pathogen, ranging from a day or two in acute diseases to months or years in chronic diseases[37][40]. The flu virus incubates for approximately 1-2 days before symptom onset[37], while Hepatitis B virus incubation ranges from 45 to 180 days before initial clinical manifestations[37]. Salmonella, a common foodborne bacterium, causes symptoms within 6 hours to 6 days post-exposure[37]. The length of the incubation period depends on multiple factors including the pathogen replication rate, the route of entry, the size of the initial bacterial or viral inoculum, and individual host immune status[37][40].
The prodromal period occurs after the incubation period and before the characteristic symptoms specific to a particular infection appear[37][40]. During this phase, the pathogen continues replicating while the host begins experiencing general signs and symptoms of illness, which typically result from activation of the immune system rather than direct pathogenic damage[37][40]. Characteristic prodromal symptoms include fever, pain, soreness, swelling, and inflammation[37][40]. These symptoms are typically too general to indicate a particular disease, representing nonspecific manifestations of the host inflammatory response to pathogenic challenge[40]. Patients often become contagious during the prodromal period, contributing to disease transmission in populations[40]. For example, patients with viral meningitis become contagious when the first signs and symptoms of the prodromal period appear[37].
The period of illness represents the third stage of infection during which the signs and symptoms of disease become most obvious and severe[40]. This stage includes the time when a person demonstrates apparent symptoms of infectious disease, with symptom characteristics varying widely depending on the underlying pathogenic cause[37]. Respiratory infections, such as the common cold or influenza, produce symptoms including cough, congestion, sore throat, and systemic malaise[37]. Gastrointestinal infections produce symptoms of diarrhea, nausea, vomiting, and abdominal pain[37]. The duration of the illness period varies dramatically depending on the type of infection, the number of infectious microbes in the body, and the strength of a person's immune system[37]. Flu symptoms typically last up to a week for many viral respiratory infections[37], while certain infections including Hepatitis B can produce symptoms lasting several weeks or even years[37]. The illness period represents the stage during which pathogenic burden is typically at maximum levels and when patients are most likely to seek medical care.
During the decline period, the immune system mounts a successful defense against pathogens, and the number of pathogenic particles begins to decrease[37][40]. Symptoms gradually improve during this stage as infectious agent burden declines[37]. However, patients may develop secondary infections during the decline period if the primary infection has significantly weakened their immune system[37][40]. The virus or bacteria can still transmit to other people during this stage despite declining clinical symptoms[37]. For influenza, the decline period typically begins after approximately one week of illness[40].
The final stage of infection is convalescence, during which symptoms resolve and a person returns to normal functions[37][40]. Depending on the severity of the infection and the specific pathogen involved, some people may experience permanent damage that the body cannot fully repair[37]. For example, severe bacterial meningitis can result in permanent hearing loss or neurological impairment even after successful bacterial clearance[37].
The duration and course of infectious disease varies dramatically depending on whether the disease progresses as an acute infection or becomes chronic or latent[40]. An acute disease shows pathologic changes occurring over a relatively short time including hours, days, or a few weeks, involving rapid onset of disease conditions[40]. Influenza exemplifies an acute disease with an incubation period of approximately 1-2 days and infected individuals spreading influenza to others for approximately 5 days after becoming ill[40]. After approximately one week, individuals typically enter the period of decline[40].
In contrast, chronic diseases persist for months or years with continued active replication of infectious agents and ongoing clinical manifestations[40]. Hepatitis B virus can cause chronic infection in some patients who do not eliminate virus after acute illness, characterized by continued production of infectious virus for 6 months or longer after acute infection[40]. Helicobacter pylori infections establish chronic colonization in the stomach unless specifically treated with antibiotics, allowing bacterial infections to recur indefinitely unless the infection is cleared[40].
In latent diseases, as opposed to chronic infections, the causal pathogen goes dormant for extended periods with no active replication[40]. Examples include herpes (HSV-1 and HSV-2), chickenpox (varicella-zoster virus), and mononucleosis (Epstein-Barr virus)[40]. HSV-1, HSV-2, and VZV evade the host immune system by residing in latent form within cells of the nervous system for long periods, but can reactivate to become active infections during times of stress and immunosuppression[40]. Varicella-zoster virus provides a striking example; initial infection results in chickenpox in childhood, followed by long latency[40]. The virus may reactivate decades later, causing shingles (herpes zoster) in adulthood[40]. Epstein-Barr virus goes into latency in B cells of the immune system and possibly epithelial cells, with capacity to reactivate years later and produce B-cell lymphoma[40].
Intracellular pathogens manipulate host metabolic systems to establish replicative niches and evade immune responses, exploiting metabolic reprogramming for pathogenic advantage[42]. Many viruses depend on host glucose metabolism to sustain their life cycles, using the host's metabolic machinery to produce viral proteins and generate energy needed for replication[39]. As a countermeasure, the immune system employs metabolic restriction strategies that limit glucose availability in infected tissues, effectively starving virus and preventing expansion[39]. This metabolic warfare demonstrates how pathogenic success depends not merely on specific virulence factors but on the broader metabolic context of infection.
During influenza virus and respiratory syncytial virus infections, alveolar macrophages (key respiratory tract defense cells) undergo metabolic reprogramming upon encountering respiratory viruses, shifting from oxidative phosphorylation to glycolysis and increasing glucose uptake via upregulation of GLUT1 transporter expression[39]. This glycolytic adaptation fuels production of pro-inflammatory cytokines including IL-6, TNF, and IL-1β[39]. The glycolytic metabolite succinate plays crucial role in amplifying inflammation by stabilizing hypoxia-inducible factor 1-alpha (HIF-1α), which drives IL-1β expression[39]. This inflammatory response proves beneficial in early infection stages, enhancing viral clearance by recruiting and activating additional immune cells[39]. However, excessive glycolytic activation can lead to immune overactivation and tissue damage characteristic of severe influenza and COVID-19[39].
Neutrophils and monocytes recruited to infection sites rely on glycolysis to generate ATP rapidly, enabling production of reactive oxygen species and antimicrobial peptides necessary for pathogen clearance[39]. Neutrophils in particular undergo hypermetabolic states characterized by increased glucose uptake and lactate production, with lactate accumulation in inflamed tissues driving further immune cell activation but potentially contributing to immunosuppressive microenvironments if unchecked[39]. Persistent hyperglycemia fuels systemic inflammation by activating pro-inflammatory pathways and increasing production of cytokines like IL-6, TNF, and IL-1β, impairing immune cell function and promoting viral replication[39]. Insulin resistance further weakens antiviral responses by limiting glucose availability for immune cells including T cells, macrophages, and natural killer cells that depend on glycolysis for activation and function[39].
Bacterial communication relies on versatile chemical signaling molecules called autoinducers, which regulate bacterial gene expression through a process known as quorum sensing[43]. This allows individual bacteria within colonies to coordinate and carry out colony-wide functions including sporulation, bioluminescence, virulence, conjugation, competence, and biofilm formation[43]. During their reproductive cycle, individual bacteria synthesize autoinducers[43]. Gram-negative bacteria produce acyl-homoserine lactone autoinducers that can passively diffuse through their thin cell walls, while gram-positive bacterial autoinducers are peptide-based and must be actively transported through the peptidoglycan cell wall using ATP-binding cassette transporter systems[43]. As bacteria reproduce and increase in number, individual cells produce progressively more autoinducers with extracellular concentration eventually exceeding intracellular levels, creating a threshold where continued outward diffusion becomes energetically unfavorable, resulting in increased intracellular autoinducer concentration[43].
Once intracellular autoinducer concentration increases, autoinducers bind to their receptors, triggering signaling cascades that alter transcription factor activity and therefore gene expression[43]. For many bacteria, changes in gene expression include downregulation of autoinducer synthesis through negative feedback loops[43]. Vibrio cholerae uses quorum sensing for virulence during cholera infection, building biofilms that help transport nutrients between colonies while simultaneously protecting them[43]. The ability to form biofilms within hosts ensures successful bacterial reproduction and eventual secretion of cholera toxin, one of two virulence factors contributing to 21,000 to 143,000 cholera deaths annually worldwide[43]. Researchers are now exploring Vibrio cholerae's quorum-sensing process as a therapeutic target, with one exciting study demonstrating that overloading Vibrio with its autoinducer can halt biofilm formation completely, potentially delaying the infectious process sufficiently for immune systems to mount effective responses[43].
Infectious disease pathophysiology emerges from the complex interplay between sophisticated pathogenic virulence mechanisms and dynamic host defensive responses operating across molecular, cellular, and systemic levels. Pathogens have evolved remarkable strategies to exploit host cell machinery through receptor-mediated entry, cytoskeletal manipulation, toxin production, complement evasion, and immune antagonism through interferon blockade. Conversely, hosts maintain multilayered defenses including pattern recognition receptors that sense pathogenic molecular patterns, inflammasome complexes that coordinate inflammatory responses, diverse antibody-mediated mechanisms that neutralize and opsonize pathogens, and cell-mediated immunity through cytotoxic T lymphocytes that eliminate infected cells. The progression of infectious disease through distinct temporal stages—from incubation through prodromal, illness, decline, and convalescence phases—reflects the kinetics of this host-pathogen competition, with clinical manifestations arising not merely from direct pathogenic damage but from the inflammatory consequences of immune activation and the metabolic perturbations induced by this systemic challenge.
Understanding these mechanisms at the molecular level provides essential foundation for rational therapeutic development. Recognition that pathogens employ quorum sensing to coordinate virulence offers opportunities for therapeutic interference with bacterial communication. Appreciation of how viruses antagonize interferon responses through multiple parallel mechanisms suggests strategies for enhancing innate immune responses. The discovery that immune cells hijack glucose metabolism to fuel antimicrobial responses while simultaneously restricting glucose availability to pathogens reveals novel metabolic intervention points. The continued elucidation of how bacterial adhesins directly manipulate host cell signaling through integrin engagement identifies additional targets for anti-adhesion therapy with potential broader efficacy across multiple gram-negative infections. Future therapeutic approaches will likely exploit this growing mechanistic understanding to develop novel interventions targeting not only pathogens themselves but also the dysregulated inflammatory responses and metabolic perturbations that ultimately cause clinical disease.